FABP4 Inhibitor Composition for Sebum Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for controlling excessive sebum secretion, such as isotretinoin, are ineffective due to significant side effects, and there is a lack of safe alternatives to treat acne and seborrheic dermatitis caused by excessive sebum production.

Innovation Solution

A composition comprising a FABP4 inhibitor, represented by Formula 1, is used to inhibit sebum secretion by reducing lipid synthesis in sebocytes and modulating lipid synthesis-related signal transduction systems, effectively treating acne and seborrheic dermatitis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If isotretinoin is used to control excessive sebum secretion, then sebum synthesis is effectively reduced, but side effects such as lipid metabolism disorders and liver toxicity occur

Engineering Contradiction:

Improvesebum synthesis reductionVSAvoidside effects including lipid metabolism disorders and liver toxicity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameter from isotretinoin (vitamin A derivative) to a FABP4 inhibitor compound, fundamentally altering the mechanism of action while achieving the same therapeutic effect of reducing sebum synthesis without the harmful side effects

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention introduces FABP4 inhibitor as an intermediary substance that blocks the fatty acid binding protein 4, thereby interfering with the lipid metabolism pathway in sebocytes to reduce sebum production without directly affecting liver function or causing teratogenicity

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If isotretinoin is used to treat acne, then sebum secretion is reduced effectively, but teratogenicity occurs in women of childbearing age

Engineering Contradiction:

Improvesebum secretion reductionVSAvoidteratogenicity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical structure and mechanism from vitamin A derivative (isotretinoin) to a FABP4 inhibitor, eliminating the teratogenic property while preserving the ability to reduce sebum secretion and treat acne

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention converts the harmful teratogenic effect into a safe treatment option by using a different molecular mechanism (FABP4 inhibition) that achieves the same therapeutic benefit without the harmful side effect, making it suitable for women of childbearing age

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20230255938A1Composition for inhibiting sebum secretion comprising FABP4 inhibitor

Publication Date: 2023.08.17 THE IND & ACADEMIC COOP IN CHUNGNAM NAT UNIV (IAC)

AI summary

The present invention relates to a composition for inhibiting sebum secretion comprising a FABP4 inhibitor, more specifically, relates to a composition for inhibiting sebum secretion capable of regulating sebum secretion by reducing lipid synthesis in sebocytes, inhibiting lipid synthesis-related signal transduction systems, and reducing the expression of lipid synthesis-related electronic factors. Also, the composition of the present invention can be used for preventing, treating or improving acne or seborrheic dermatitis.